Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice
- PMID: 9759887
Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice
Abstract
The involvement of granulocyte-macrophage CSF (GM-CSF) in collagen-induced arthritis (CIA) was examined using GM-CSF-deficient mice. Although CIA is generally considered to be restricted to mice of the H-2q or H-2r haplotypes, we examined the role of GM-CSF in the CIA model using GM-CSF-deficient (-/-) and wild-type (+/+) mice on a C57BL/6 (H-2b) background. Mice were immunized by intradermal injection at the base of the tail with chick type II collagen followed by a repeat injection 21 days later. We found, based on both clinical and histologic assessments, that wild-type mice on this background developed severe CIA, while the GM-CSF-deficient mice had virtually no disease. Mice that were heterozygous for the GM-CSF gene (+/-) collectively displayed an intermediate response between those of the GM-CSF(+/+) and GM-CSF(-/-) groups, suggesting a gene dosage effect. GM-CSF(+/+) and GM-CSF(+/-) mice exhibited CIA responses ranging from mild (single digits) to severe swelling of all four paws, while in the few GM-CSF(-/-) mice that developed CIA the disease was confined to single digits. Despite the putative role of GM-CSF in dendritic cell development, GM-CSF-deficient mice exhibited both humoral and cellular (delayed-type hypersensitivity) responses to type II collagen; however, the cellular response was significantly reduced in the GM-CSF-deficient mice compared with the wild-type controls. These findings suggest that GM-CSF is required for CIA development in mice and support the idea that GM-CSF is a key cytokine in inflammatory joint disease.
Similar articles
-
The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF.J Leukoc Biol. 2000 Jul;68(1):144-50. J Leukoc Biol. 2000. PMID: 10914502
-
Reduced susceptibility to collagen-induced arthritis in mice deficient in IFN-gamma receptor.J Immunol. 1998 Aug 1;161(3):1542-8. J Immunol. 1998. PMID: 9686622
-
Granulocyte macrophage colony-stimulating factor expression by both renal parenchymal and immune cells mediates murine crescentic glomerulonephritis.J Am Soc Nephrol. 2005 Sep;16(9):2646-56. doi: 10.1681/ASN.2004121107. Epub 2005 Jul 20. J Am Soc Nephrol. 2005. PMID: 16033860
-
Extra-pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte-macrophage colony-stimulating factor-deficient mice.Respirology. 2006 Jan;11 Suppl:S16-22. doi: 10.1111/j.1440-1843.2006.00801.x. Respirology. 2006. PMID: 16423263 Review.
-
GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.Expert Rev Clin Immunol. 2015 Apr;11(4):457-65. doi: 10.1586/1744666X.2015.1024110. Epub 2015 Mar 8. Expert Rev Clin Immunol. 2015. PMID: 25748625 Review.
Cited by
-
GM-CSF: An immune modulatory cytokine that can suppress autoimmunity.Cytokine. 2015 Oct;75(2):261-71. doi: 10.1016/j.cyto.2015.05.030. Epub 2015 Jun 22. Cytokine. 2015. PMID: 26113402 Free PMC article. Review.
-
Human antibodies for immunotherapy development generated via a human B cell hybridoma technology.Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3557-62. doi: 10.1073/pnas.0511285103. Epub 2006 Feb 27. Proc Natl Acad Sci U S A. 2006. PMID: 16505368 Free PMC article.
-
Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease.Arthritis Res. 2001;3(5):293-8. doi: 10.1186/ar318. Epub 2001 Jun 11. Arthritis Res. 2001. PMID: 11549370 Free PMC article.
-
Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization.Pain Rep. 2018 Sep 17;3(5):e676. doi: 10.1097/PR9.0000000000000676. eCollection 2018 Sep-Oct. Pain Rep. 2018. PMID: 30534627 Free PMC article.
-
Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement.Arthritis Res Ther. 2010;12(2):R37. doi: 10.1186/ar2946. Epub 2010 Mar 2. Arthritis Res Ther. 2010. PMID: 20196869 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases